HOME > CORPORATE PROFILE > Global Activities

Global Activities

Contributing to worldwide human health through a global network

In 1950, Fujizoki Pharmaceutical Co., Ltd (the present "Fujirebio Inc." ) was established as a company manufacturing and selling pharmaceutical products.

Fujirebio's overseas activities began in 1969 with the internationally acclaimed Treponema pallidum hemagglutination assay (TPHA), a serodiagnostic test for the detection of syphilis. The improved version of this test is now sold as SERODIA® -TP・PA.

Over the years, Fujirebio has established a solid global network with manufacturing bases in the U.S. and Asia. In 1998, Fujirebio acquired the production and marketing rights for tumor markers of Centocor, Inc., and founded Fujirebio Diagnostics Inc. (FDI) with its first manufacturing base in the U.S. In July 2001, FDI was integrated with Fujirebio America Inc., and the new consolidated firm gained greater grounds on the U.S. market especially for tumor markers and blood screening tests. This important step also secured Fujirebio's foundations as a global life-science company.

Fujirebio now supplies a wide range of products for the early detection and diagnosis of various infectious diseases to more than 100 nations, through an extensive network of distributors located in 70 countries. Fujirebio also actively participates in disease prevention projects run by the WHO and UNICEF. Through these efforts, Fujirebio keeps its vigorous position in the worldwide healthcare standards and is expanding its global business.

Click here to view our history

The Origin of Fujirebio

In touch with life

According to the World Health Organization (WHO), a large number of children are still the victims of infectious diseases. Over the past 20 years, about 30 new infectious diseases have been discovered. To overcome these and other intractable diseases, it is crucial to adopt reliable disease-prevention measures and accurate early diagnosis techniques. For over 50 years, Fujirebio has strived to respond to these pressing medical needs.

The company name is a fusion of FUJI, from Japan's cherished icon, Mt. Fuji, RE from the word 'revival', and BIO from the Greek bios, meaning life. The name is intended to symbolize the restoration of health.


Miraca Holdings
Fujirebio Inc. is a member of Miraca Group.